GSK warned about misleading TV ad
Pharma Compliance Alert, March 11, 2009
A direct-to-consumer television ad misbrands GlaxoSmithKline’s prostate drug Avodart, according to an FDA warning letter.
The 60-second ad presents misleading comparative claims and overstates the efficacy of Avodart. Specifically, the ad claims Avodart is the only medication that shirks the prostate. Merck’s Proscar also reduces the size of the prostate and has a similar indication. Visual effects in the ad also exaggerate Avodart’s effectiveness, according to the FDA.
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q/A: Coding for telescopic intraocular lens
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched
